Prostate Cancer

Prostate cancer is the second-leading cause of cancer deaths and the second-most-common cancer in men. The American Cancer Society estimates the disease will strike more than 190,000 men this year and cause more than 33,000 deaths. But doctors say many lives can be saved with annual screenings. Sound familiar? There is similar information shared every October for breast cancer awareness. “It's the men’s equivalent of breast cancer in women – the caveat being: It’s not as lethal as breast cancer,” said Dr. Gideon Lorber, a UPMC urologist who sees patients at UPMC Somerset. “It is definitely something that we would like to screen for,” he said. Dr. Gideon Lorber SUBMITTED PHOTO The prostate is walnut-sized a gland that produces some of the fluid that carries sperm. Located below a man’s bladder, it surrounds the urethra, the tube through which urine passes out of the body. Screening for prostate cancer begins with a simple blood test to check levels of prostate...

Al Roker Says He's 'Back Home' Following Prostate Cancer Surgery | PEOPLE.com Skip to content Top Navigation Close Explore PEOPLE.com Profile Menu Follow us Close Share options Close View image Al Roker Says He's 'Back Home' Following Prostate Cancer Surgery: 'See You All Soon' this link is to an external site that may or may not meet accessibility guidelines.

New Cars Used Cars of Search Cars Powered by Cars.com

There are several life-prolonging treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but there isn’t a lot of information about patient experiences with these treatments. For a recent study, researchers interviewed patients to glean their perspectives on and experiences with life-prolonging treatments. “Given the severity of mCRPC, it is important to consider the possible negative effects of specific treatments on the patients’ [health-related quality of life] and weigh these against the desired positive effects,” the study authors explained. “Still, it has been shown that men with mCRPC lack enough information about the treatments and their possible impact of them on their life.” Sixteen men with mCRPC who were initiating (n=3), were undergoing (n=9), or just finished their first life-prolonging treatment (n=4) of either chemotherapy (Docetaxel, n=11) or hormone-regulating therapy (Abiraterone acetate, n=1; Enzalutamide, n=4) were intervi...

MARQUETTE, Mich. (UPHS) - UP Health System – Marquette joins in recognizing Men’s Health Awareness Month this November, also known as “Movember.” UP Health System – Marquette is urging men to take charge of their prostate health this month and throughout the year. Prostate cancer is the most common cancer in American men, with more than 183,000 new cases diagnosed each year, according to the Centers for Disease Control (CDC). When it comes to men’s health, screening for prostate cancer regularly should be a top priority. Detect Disease Early with Regular Check-ups and Exams According to research from the CDC, women are more likely than men to visit the doctor for annual exams and preventive services. Regular check-ups with a primary care physician could help flag issues – even those that are not as obvious – before they become a real problem. Prostate cancer can be detected early through regular screenings. This is particularly important for more at-risk populations, such as men ...

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease. The new gene signature may also be useful for evaluating responses to treatment and for developing new therapies to prevent or treat advanced prostate cancer. “If we could know in advance which patients will develop metastases, we could start treatments earlier and treat the cancer more aggressively,” says the study’s senior author, Cory Abate-Shen, PhD, chair of the Department of Molecular Pharmacology and Therapeutics, the Michael and Stella Chernow Professor of Urologic Sciences (in Urology), and professor of pathology & cell biology (in the Herbert Irving Comprehensive Cancer Center) at Columbia University Vagelos College of Physicians and Surgeons. “Conversely, patients whose...

Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer. The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026. Download Free Report Sample @ https://ift.tt/37hUVcV The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of pro...